Results from Bristol Myers' (BMY), AstraZeneca's (AZN) dapagliflozin and ONGLYZA(TM) Studies Presented at ADA
Tweet Send to a Friend
Results from a 12-week study demonstrated that the investigational drug dapagliflozin, a novel, selective, sodium glucose co-transporter 2 inhibitor, produced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
